Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients
PKTR who are EBV-naïve prior to transplantation are expected to have a higher prevalence of EBV DNAemia. We found that PKTR who were EBV seronegative prior to transplantation were less likely to achieve EBV clearance in response to immunosuppression dose reduction. We suggest that rituximab therapy in PKTR may be safe and effective in EBV clearance and PTLD prevention.
Authors
- Shirley Pollack (ORCID: https://orcid.org/0000-0002-9129-3165)
- Moran Plonsky
- Rami Tibi
- Israel Eisenstein
- Daniella Magen (ORCID: https://orcid.org/0000-0001-8825-5259)
- Irina Libinson-Zebegret
- Renata Yakobov
Institutions
- Technion – Israel Institute of Technology (IL)
- Rambam Health Care Campus (IL)
Publication Details
- Journal
- Pediatric Nephrology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1007/s00467-024-06522-2
- Citations
- 4
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Technion-Israel Institute of Technology